MX2014015615A - Uso de citrato ferrico en el tratamiento de pacientes con enfermedad renal cronica. - Google Patents
Uso de citrato ferrico en el tratamiento de pacientes con enfermedad renal cronica.Info
- Publication number
- MX2014015615A MX2014015615A MX2014015615A MX2014015615A MX2014015615A MX 2014015615 A MX2014015615 A MX 2014015615A MX 2014015615 A MX2014015615 A MX 2014015615A MX 2014015615 A MX2014015615 A MX 2014015615A MX 2014015615 A MX2014015615 A MX 2014015615A
- Authority
- MX
- Mexico
- Prior art keywords
- iron
- patients
- reduce
- increase
- ferric citrate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/295—Iron group metal compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261662565P | 2012-06-21 | 2012-06-21 | |
| US201361757229P | 2013-01-28 | 2013-01-28 | |
| US201361800618P | 2013-03-15 | 2013-03-15 | |
| US201361801050P | 2013-03-15 | 2013-03-15 | |
| PCT/US2013/047134 WO2013192565A2 (en) | 2012-06-21 | 2013-06-21 | Use of ferric citrate in the treatment of chronic kidney disease patients |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2014015615A true MX2014015615A (es) | 2015-03-20 |
Family
ID=49769729
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014015615A MX2014015615A (es) | 2012-06-21 | 2013-06-21 | Uso de citrato ferrico en el tratamiento de pacientes con enfermedad renal cronica. |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US20130345303A1 (enExample) |
| EP (3) | EP4335436A3 (enExample) |
| JP (4) | JP2015535209A (enExample) |
| KR (2) | KR102150135B1 (enExample) |
| CN (2) | CN104884055A (enExample) |
| AU (2) | AU2013278000A1 (enExample) |
| BR (1) | BR112014032049A2 (enExample) |
| CA (1) | CA2876982A1 (enExample) |
| DK (1) | DK3730136T3 (enExample) |
| EA (1) | EA201590062A1 (enExample) |
| ES (2) | ES2970050T3 (enExample) |
| FR (1) | FR25C1043I1 (enExample) |
| HK (1) | HK1214503A1 (enExample) |
| IL (1) | IL236356A0 (enExample) |
| MX (1) | MX2014015615A (enExample) |
| NO (1) | NO2025048I1 (enExample) |
| PL (1) | PL3730136T3 (enExample) |
| SG (2) | SG11201408521WA (enExample) |
| WO (1) | WO2013192565A2 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2768656C (en) | 2009-07-21 | 2016-10-04 | Keryx Biopharmaceuticals, Inc. | Ferric citrate dosage forms |
| TWI653043B (zh) * | 2012-12-20 | 2019-03-11 | 瑞士商伊蘭科動物健康公司 | 新用途 |
| LT3003327T (lt) | 2013-06-05 | 2017-12-27 | Tricida Inc. | Protonus surišantys polimerai, skirti geriamajam vartojimui |
| ES2856261T3 (es) * | 2013-10-01 | 2021-09-27 | Fresenius Medical Care Deutschland Gmbh | Método y aparatos para determinar una pérdida diaria de hierro de un paciente |
| EA201690926A1 (ru) * | 2013-11-04 | 2016-09-30 | Керикс Байофармасьютикалз, Инк. | Цитрат железа (iii) для уменьшения сердечной недостаточности у пациентов с хроническим заболеванием почек |
| WO2015110968A1 (en) * | 2014-01-23 | 2015-07-30 | Lupin Limited | Pharmaceutical grade ferric citrate and method for its production |
| WO2015198304A1 (en) | 2014-06-22 | 2015-12-30 | Dexcel Pharma Technologies Ltd. | Pharmaceutical compositions comprising ferric citrate and methods for the production thereof |
| CN113855703B (zh) | 2014-12-10 | 2025-11-25 | 特里赛达公司 | 用于口服施用的质子结合聚合物 |
| AU2016226250B2 (en) * | 2015-03-04 | 2021-05-27 | Keryx Biopharmaceuticals, Inc. | Use of ferric citrate in the treatment of iron-deficiency anemia |
| CN104688706B (zh) * | 2015-04-01 | 2017-07-14 | 成都欣捷高新技术开发有限公司 | 一种高载药量、快速溶出的枸橼酸铁组合物及其制备方法 |
| WO2016162794A1 (en) * | 2015-04-08 | 2016-10-13 | Leiutis Pharmaceuticals Pvt Ltd | Pharmaceutical compositions of ferric citrate |
| WO2016162888A1 (en) * | 2015-04-09 | 2016-10-13 | Actavis Group Ptc Ehf. | Process for preparing pharmaceutical grade ferric citrate |
| WO2017193024A1 (en) | 2016-05-06 | 2017-11-09 | Tricida, Inc. | Hcl-binding compositions for and method of treating acid-base disorders |
| US20210085711A1 (en) | 2017-09-19 | 2021-03-25 | Japan Tobacco Inc. | Use of ferric citrate in prevention and/or treatment of iron-deficiency anemia in hypermenorrhea patient and/or patient suffering from hypermenorrhea-associated gynecologic disease |
| AU2018360867B2 (en) | 2017-11-03 | 2024-12-12 | Tricida, Inc. | Compositions for and method of treating acid-base disorders |
| WO2019236639A1 (en) * | 2018-06-04 | 2019-12-12 | Tricida, Inc. | Method of treating acid-base disorders |
| CN113613662A (zh) | 2018-10-29 | 2021-11-05 | 法码科思莫斯控股有限公司 | 用羧基麦芽糖铁治疗铁缺乏 |
| WO2022150623A1 (en) | 2021-01-08 | 2022-07-14 | Akebia Therapeutics, Inc. | Compounds and composition for the treatment of anemia |
| WO2022251563A1 (en) | 2021-05-27 | 2022-12-01 | Keryx Biopharmaceuticals, Inc. | Pediatric formulations of ferric citrate |
| CN115024495B (zh) * | 2022-06-27 | 2024-03-22 | 北京金康普食品科技有限公司 | 改善肾病患者钙磷代谢的营养组合物及其应用 |
| WO2025181559A1 (en) * | 2024-02-29 | 2025-09-04 | Sloiron, Inc. | Methods for determining the amount of encapsulated and free iron in a sample |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20000067929A (ko) * | 1996-07-19 | 2000-11-25 | 나가타 코이치 | 고인혈증 치료제 |
| US5753706A (en) * | 1996-12-16 | 1998-05-19 | Hsu; Chen Hsing | Methods for treating renal failure |
| US8093423B2 (en) | 2003-02-19 | 2012-01-10 | Globoasia, Llc | Pharmaceutical-grade ferric organic compounds, uses thereof and method of making same |
| TWI335218B (en) * | 2003-02-19 | 2011-01-01 | Panion & Bf Biotech Inc | Ferric organic compounds, uses thereof and methods of making same |
| CN1600302A (zh) * | 2003-09-22 | 2005-03-30 | 宝龄富锦生技股份有限公司 | 含有柠檬酸铁的医药组合物以及药用级柠檬酸铁及其制法和含有药用级柠檬酸铁的膳食营养品 |
| US20060134227A1 (en) * | 2004-12-22 | 2006-06-22 | Bortz Jonathan D | Compositions including iron |
| MY162727A (en) | 2005-08-18 | 2017-07-14 | Panion & Bf Biotech Inc | Pharmaceutical-grade ferric organic compounds, uses thereof, and methods of making the same |
| EP3081219A1 (en) * | 2006-01-06 | 2016-10-19 | Luitpold Pharmaceuticals, Inc. | Methods and compositions for administration of iron |
| CN101374416A (zh) * | 2006-01-30 | 2009-02-25 | 环亚有限公司 | 逆转、防止、延迟或稳定软组织钙化的方法 |
| CA2768656C (en) * | 2009-07-21 | 2016-10-04 | Keryx Biopharmaceuticals, Inc. | Ferric citrate dosage forms |
-
2013
- 2013-06-21 EA EA201590062A patent/EA201590062A1/ru unknown
- 2013-06-21 SG SG11201408521WA patent/SG11201408521WA/en unknown
- 2013-06-21 EP EP23219273.2A patent/EP4335436A3/en not_active Withdrawn
- 2013-06-21 ES ES20163104T patent/ES2970050T3/es active Active
- 2013-06-21 JP JP2015518623A patent/JP2015535209A/ja active Pending
- 2013-06-21 KR KR1020157001458A patent/KR102150135B1/ko active Active
- 2013-06-21 SG SG10201805177PA patent/SG10201805177PA/en unknown
- 2013-06-21 DK DK20163104.1T patent/DK3730136T3/da active
- 2013-06-21 HK HK16102352.0A patent/HK1214503A1/zh unknown
- 2013-06-21 ES ES13807102T patent/ES2796254T3/es active Active
- 2013-06-21 EP EP20163104.1A patent/EP3730136B1/en active Active
- 2013-06-21 WO PCT/US2013/047134 patent/WO2013192565A2/en not_active Ceased
- 2013-06-21 US US13/924,332 patent/US20130345303A1/en not_active Abandoned
- 2013-06-21 CN CN201380044271.0A patent/CN104884055A/zh active Pending
- 2013-06-21 EP EP13807102.2A patent/EP2863906B1/en active Active
- 2013-06-21 PL PL20163104.1T patent/PL3730136T3/pl unknown
- 2013-06-21 BR BR112014032049A patent/BR112014032049A2/pt not_active IP Right Cessation
- 2013-06-21 CN CN202110644193.4A patent/CN113244209A/zh active Pending
- 2013-06-21 AU AU2013278000A patent/AU2013278000A1/en not_active Abandoned
- 2013-06-21 CA CA2876982A patent/CA2876982A1/en not_active Abandoned
- 2013-06-21 MX MX2014015615A patent/MX2014015615A/es unknown
- 2013-06-21 KR KR1020207024260A patent/KR20200103855A/ko not_active Ceased
-
2014
- 2014-04-25 US US14/262,465 patent/US20140234416A1/en not_active Abandoned
- 2014-10-24 US US14/523,656 patent/US20150079168A1/en not_active Abandoned
- 2014-12-18 IL IL236356A patent/IL236356A0/en unknown
-
2018
- 2018-04-10 JP JP2018075243A patent/JP2018138562A/ja active Pending
- 2018-05-08 AU AU2018203205A patent/AU2018203205B2/en not_active Ceased
-
2020
- 2020-02-25 JP JP2020029756A patent/JP2020100638A/ja active Pending
-
2022
- 2022-02-10 JP JP2022019167A patent/JP2022070945A/ja active Pending
-
2025
- 2025-11-06 NO NO2025048C patent/NO2025048I1/no unknown
- 2025-11-18 FR FR25C1043C patent/FR25C1043I1/fr active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG10201805177PA (en) | Use of ferric citrate in the treatment of chronic kidney disease patients | |
| MX2016005734A (es) | Citrato férrico para reducir falla cardíaca en pacientes con enfermedad renal crónica. | |
| AR061170A1 (es) | Proteinas que se unen con el factor de crecimiento de hepatocitos (hgf) | |
| EA201591427A1 (ru) | Соединения и их применения для модуляции гемоглобина | |
| UY35313A (es) | Antiadhesion de leucocitos para mitigar los potenciales eventos adversos causados por los dominios de unión específicos de cd3 | |
| BR112015016681A8 (pt) | uso de nanopartículas compreendendo paclitaxel e uma albumina, kit, medicamento, composição e forma de dosagem unitária para tratamento de câncer pancreático | |
| MY183637A (en) | Compounds and uses thereof for the modulation of hemoglobin | |
| EA201890278A1 (ru) | Антитела к pd-l1 | |
| BR112012033044A2 (pt) | composição de precursor de diálise | |
| IN2014DN11099A (enExample) | ||
| MY191087A (en) | Compounds and uses thereof for the modulation of hemoglobin | |
| BR112015027282A2 (pt) | fenfluramina para uso no tratamento de síndrome de dravet | |
| MX2016016531A (es) | Metodos y composiciones para el tratamiento de las ulceras. | |
| EA201491584A1 (ru) | Способы лечения немелкоклеточного рака легких c применением комбинированного лечения с ингибитором киназы tor | |
| MX2020000083A (es) | Factor de von willebrand recombinante ( rvwf ) y factor viii recombinante ( rfviii ) para usarse en un metodo para tratar la enfermedad de von willebrand. | |
| MY178654A (en) | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or an anti-adm non-ig protein scaffold for use in therapy | |
| EA201690528A1 (ru) | Способы лечения злокачественной опухоли непрерывной инфузией кофермента q10 | |
| EA201591424A1 (ru) | Способы лечения дефицита железа растворимым пирофосфатом железа | |
| WO2010119991A3 (en) | Anti-hgf antibody combinational cancer therapies | |
| BR112014009414A2 (pt) | uso de micelas de proteína de soro do leite para melhorar o perfil de insulina em pacientes diabéti-cos | |
| EA201500232A1 (ru) | Три(гетеро)арилпиразолы и их применение | |
| EA201891922A1 (ru) | Лекарственное средство для лечения инфекций на фоне диабетической стопы | |
| NZ725920A (en) | Use of ferric citrate in the treatment of chronic kidney disease patients | |
| Al-Hashimi et al. | Binding of anti-GRP78 autoantibodies to cell surface GRP78 promotes cancer progression by activating tissue factor procoagulant activity | |
| UA59041U (ru) | Способ лечения больных с сахарным диабетом 2-го типа |